CorMedix Appoints Greg Duncan to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ

CorMedix Appoints Greg Duncan to its Board

Seasoned industry veteran with decades of

strategic and commercial leadership experience in the pharmaceutical sector

Berkeley Heights, NJ - November 2, 2020 - CorMedix

Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the

prevention and treatment of infectious and inflammatory disease, today announced the appointment of Greg Duncan to its Board of

Directors. Greg will replace Dr. Mehmood Khan, who is stepping down from the Board due to policies in place with his new role within

an investment organization.

"We thank Mehmood for his service to CorMedix and strategic

advice as we have continued to advance Defencath, our lead program for the prevention of catheter related blood stream infections

in hemodialysis patients," said Khoso Baluch, Chief Executive Officer of CorMedix.

"Greg will be a tremendous asset to our Board as he brings

decades of commercial leadership experience across a range of medicines as well as experience in strategic transactions

during his time at both Pfizer and UCB. These experiences will be invaluable to CorMedix as we plan our evolution into a commercial

stage company over the year ahead."

Greg Duncan, an industry veteran with many years of senior leadership

experience at Pfizer and UCB, commented "After reviewing Cormedix's accomplishments and the potential commercial opportunity

for Defencath, I am pleased to join the Company's Board of Directors. Given the upcoming PDUFA date and the potential advantages

of this innovative catheter lock solution, I believe that Cormedix will succeed in making Defencath available to patients in need."

Dr. Khan further commented, "I have enjoyed working closely

with CorMedix and its excellent senior leadership team. While my roles and responsibilities have evolved, I look forward to following

the Company closely and seeing its exciting product opportunity advance as a material shareholder and as a supporter of the Company."

Greg currently serves as the Chairman and CEO of Virios Therapeutics,

a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated

with a viral triggered abnormal immune response, such as fibromyalgia (FM). Prior to joining his current company earlier this year,

Greg served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare,

inflammatory diseases.

Greg spent the majority of his career in senior leadership roles

in commercial stage pharmaceutical companies. He served as a senior executive at UCB, including as President of its North America

business. In addition to acting on the executive committee and guiding the strategic direction for the Company's specialty

biopharma business, Greg was responsible for managing a multi-billion dollar global business and overseeing the launches of multiple

Prior to his roles with UCB, Greg spent approximately 18 years at

Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and

later as President of Pfizer's Latin America business.

Greg received his undergraduate degree from the State University

of New York, Albany, and earned an MBA degree from Emory University.

CorMedix Inc. is a biopharmaceutical company

focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory

diseases. The Company is focused on developing its lead product Defencath , a novel, antibacterial and antifungal solution

designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients

undergoing chronic hemodialysis. Defencath's NDA has been filed and accepted for priority review with a PDUFA date of February

28, 2021. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional

five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the

NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition

patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in

surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based

therapies for rare pediatric cancers. Neutrolin is CE Marked and marketed in Europe and other territories as a medical

device. For more information, visit: www.cormedix.com.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties.

All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or

CorMedix's prospects, future financial position, financing plans, future revenues and projected costs should be considered

forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety

of important factors, including: the results of our discussions with the FDA regarding the Defencath development path, including

whether a second Phase 3 clinical trial will be required for approval of Defencath's marketing approval; the resources needed

to secure approval of the new drug application for Defencath from the FDA; the risks and uncertainties associated with CorMedix's

ability to manage its limited cash resources and the impact on current, planned or future research, including the continued development

of Defencath/Neutrolin and research for additional uses for taurolidine; obtaining additional financing to support CorMedix's

research and development and clinical activities and operations; preclinical results are not indicative of success in clinical

trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel

to staff our operations appropriately. At this time, we are unable to assess whether, and to what extent, the uncertainty surrounding

the Coronavirus pandemic may impact our business and operations. These and other risks are described in greater detail in CorMedix's

filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from

CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should

not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking

statements, except as required by law.